Product Overview

Voglibose IP 0.3 mg + Repaglinide IP 1 mg is a combination antidiabetic formulation developed for the effective management of Type 2 Diabetes Mellitus under medical supervision. The formulation combines two complementary active ingredients that work together to help control blood glucose levels, particularly after meals, and support overall glycemic management. It is designed to provide comprehensive diabetic care by addressing multiple pathways involved in glucose regulation, helping patients achieve better metabolic control and improved treatment outcomes.

Voglibose is an alpha-glucosidase inhibitor that works by delaying the digestion and absorption of carbohydrates in the intestine. This action helps reduce post-meal blood sugar spikes and promotes smoother glucose control throughout the day. By slowing carbohydrate breakdown, Voglibose assists in maintaining more stable blood glucose levels after meals.

Repaglinide belongs to a class of medicines known as meglitinides and works by stimulating the pancreas to release insulin when required. Its rapid onset of action helps control blood sugar levels around mealtimes, supporting effective postprandial glucose management and overall glycemic control.

The combination of Voglibose and Repaglinide offers a dual mechanism of action that helps manage blood sugar fluctuations more effectively than either component alone. It is commonly prescribed as part of a comprehensive diabetes management plan that includes dietary modifications, regular exercise, and lifestyle changes. Manufactured under strict WHO-GMP quality standards, the formulation ensures safety, efficacy, and consistent therapeutic performance.

Key Features

• Dual-action antidiabetic formulation
• Supports post-meal blood glucose control
• Helps maintain stable sugar levels
• Assists in comprehensive diabetes management
• Reliable and consistent therapeutic performance
• Manufactured under strict WHO-GMP standards
• Produced using advanced pharmaceutical processes

Uses

• Type 2 Diabetes Mellitus management
• Postprandial blood glucose control
• Glycemic management support
• Metabolic health management under medical supervision

How It Works

Voglibose delays carbohydrate digestion and absorption, reducing post-meal glucose spikes. Repaglinide stimulates insulin release from the pancreas, helping the body utilize glucose more effectively. Together, they provide enhanced blood sugar control and support long-term diabetes management.

Possible Side Effects

Common side effects may include:

• Nausea
• Abdominal discomfort
• Bloating or gas
• Diarrhea
• Headache
• Dizziness
• Low blood sugar (hypoglycemia)

Patients should seek immediate medical attention if severe allergic reactions, persistent hypoglycemia, or unusual symptoms occur.

Precautions

• Use only under medical supervision
• Monitor blood glucose levels regularly
• Follow prescribed dietary and exercise recommendations
• Inform your doctor about liver, kidney, or heart conditions
• Avoid self-medication or dosage adjustments without professional advice
• Pregnant or breastfeeding women should consult a healthcare professional before use

Storage Instructions

Store in a cool, dry place away from direct sunlight and moisture. Keep out of reach of children and use before the expiry date mentioned on the packaging.

Quality Assurance

Voglibose IP 0.3 mg + Repaglinide IP 1 mg is manufactured in WHO-GMP certified facilities under stringent quality control procedures. Every batch undergoes comprehensive testing to ensure safety, purity, efficacy, and pharmaceutical consistency, delivering dependable therapeutic performance and high-quality healthcare solutions.